Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088270 · ClinicalTrials.gov registry record · Phase 2
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00088270 is a Phase 2 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT00088270, a Phase 2 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.
Interventions
- DRUG OSI-7904L
- DRUG 5-Fluorouracil/Leucovorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088270
The ClinicalTrials.gov registry entry for NCT00088270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OSI-7904L is the first listed.
NCT00088270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088270 about?
NCT00088270 is a clinical study titled "A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer". Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.
What is the current status of trial NCT00088270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2004-08. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00088270?
The interventions under investigation include: OSI-7904L (DRUG), 5-Fluorouracil/Leucovorin (DRUG).
Who is sponsoring clinical trial NCT00088270?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.